Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Eli Lilly licenses Sangamo's BBB-penetrating AAV capsid for CNS disease with $18M upfront; deal includes option for 4 more ...

Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with ...

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal ...

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an additional $1.4 billion. In return, Lilly ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Sangamo (SGMO) shares are up 33c, or 53%, to 95c in after-hours trading after the company announced the deal with Eli Lilly (LLY).Don't Miss ...

Shares of Eli Lilly & Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by ...